• Je něco špatně v tomto záznamu ?

Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation

D. Panek, A. Więckowska, T. Wichur, M. Bajda, J. Godyń, J. Jończyk, K. Mika, J. Janockova, O. Soukup, D. Knez, J. Korabecny, S. Gobec, B. Malawska,

. 2017 ; 125 (-) : 676-695. [pub] 20160926

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023647

The complexity of Alzheimer's disease (AD) calls for search of multifunctional compounds as potential candidates for effective therapy. A series of phthalimide and saccharin derivatives linked by different alicyclic fragments (piperazine, hexahydropyrimidine, 3-aminopyrrolidine or 3-aminopiperidine) with phenylalkyl moieties attached have been designed, synthesized, and evaluated as multifunctional anti-AD agents with cholinesterase, β-secretase and β-amyloid inhibitory activities. In vitro studies showed that the majority of saccharin derivatives with piperazine moiety and one phthalimide derivative with 3-aminopiperidine fragment exhibited inhibitory potency toward acetylcholinesterase (AChE) with EeAChE IC50 values ranging from 0.83 μM to 19.18 μM. The target compounds displayed inhibition of human β-secretase-1 (hBACE1) ranging from 26.71% to 61.42% at 50 μM concentration. Among these compounds, two multifunctional agents (26, [2-(2-(4-benzylpiperazin-1-yl)ethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide] and 52, 2-(2-(3-(3,5-difluorobenzylamino)piperidin-1-yl)ethyl)isoindoline-1,3-dione) have been identified. Compound 26 exhibited the highest inhibitory potency against EeAChE (IC50 = 0.83 μM) and inhibitory activity against hBACE1 (33.61% at 50 μM). Compound 52 is a selective AChE inhibitor (IC50 AChE = 6.47 μM) with BACE1 inhibitory activity (26.3% at 50 μM) and it displays the most significant Aβ anti-aggregating properties among all the obtained compounds (39% at 10 μM). Kinetic and molecular modeling studies indicate that 26 may act as non-competitive AChE inhibitor able to interact with both catalytic and peripheral active site of the enzyme.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023647
003      
CZ-PrNML
005      
20170906131710.0
007      
ta
008      
170720s2017 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2016.09.078 $2 doi
035    __
$a (PubMed)27721153
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Panek, Dawid $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
245    10
$a Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation / $c D. Panek, A. Więckowska, T. Wichur, M. Bajda, J. Godyń, J. Jończyk, K. Mika, J. Janockova, O. Soukup, D. Knez, J. Korabecny, S. Gobec, B. Malawska,
520    9_
$a The complexity of Alzheimer's disease (AD) calls for search of multifunctional compounds as potential candidates for effective therapy. A series of phthalimide and saccharin derivatives linked by different alicyclic fragments (piperazine, hexahydropyrimidine, 3-aminopyrrolidine or 3-aminopiperidine) with phenylalkyl moieties attached have been designed, synthesized, and evaluated as multifunctional anti-AD agents with cholinesterase, β-secretase and β-amyloid inhibitory activities. In vitro studies showed that the majority of saccharin derivatives with piperazine moiety and one phthalimide derivative with 3-aminopiperidine fragment exhibited inhibitory potency toward acetylcholinesterase (AChE) with EeAChE IC50 values ranging from 0.83 μM to 19.18 μM. The target compounds displayed inhibition of human β-secretase-1 (hBACE1) ranging from 26.71% to 61.42% at 50 μM concentration. Among these compounds, two multifunctional agents (26, [2-(2-(4-benzylpiperazin-1-yl)ethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide] and 52, 2-(2-(3-(3,5-difluorobenzylamino)piperidin-1-yl)ethyl)isoindoline-1,3-dione) have been identified. Compound 26 exhibited the highest inhibitory potency against EeAChE (IC50 = 0.83 μM) and inhibitory activity against hBACE1 (33.61% at 50 μM). Compound 52 is a selective AChE inhibitor (IC50 AChE = 6.47 μM) with BACE1 inhibitory activity (26.3% at 50 μM) and it displays the most significant Aβ anti-aggregating properties among all the obtained compounds (39% at 10 μM). Kinetic and molecular modeling studies indicate that 26 may act as non-competitive AChE inhibitor able to interact with both catalytic and peripheral active site of the enzyme.
650    _2
$a aminy $x chemie $x farmakologie $7 D000588
650    _2
$a sekretasy $x metabolismus $7 D053829
650    _2
$a amyloidní beta-protein $x metabolismus $7 D016229
650    _2
$a vazebná místa $7 D001665
650    _2
$a hematoencefalická bariéra $x účinky léků $7 D001812
650    _2
$a cholinesterasy $x metabolismus $7 D002802
650    _2
$a systémy cílené aplikace léků $7 D016503
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a inhibitory enzymů $x chemická syntéza $x chemie $x farmakologie $7 D004791
650    _2
$a lidé $7 D006801
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a molekulární struktura $7 D015394
650    _2
$a peptidové fragmenty $x metabolismus $7 D010446
650    _2
$a ftalimidy $x chemická syntéza $x chemie $x farmakologie $7 D010797
650    _2
$a patologická konformace proteinů $7 D066263
650    _2
$a vazba proteinů $x účinky léků $7 D011485
650    _2
$a sacharin $x chemická syntéza $x chemie $x farmakologie $7 D012439
655    _2
$a časopisecké články $7 D016428
700    1_
$a Więckowska, Anna $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
700    1_
$a Wichur, Tomasz $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
700    1_
$a Bajda, Marek $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
700    1_
$a Godyń, Justyna $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
700    1_
$a Jończyk, Jakub $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
700    1_
$a Mika, Kamil $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
700    1_
$a Janockova, Jana $u Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Knez, Damijan $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
700    1_
$a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Gobec, Stanislav $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
700    1_
$a Malawska, Barbara $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland. Electronic address: mfmalaws@cyf-kr.edu.pl.
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 125, č. - (2017), s. 676-695
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27721153 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170906132309 $b ABA008
999    __
$a ok $b bmc $g 1239328 $s 984560
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 125 $c - $d 676-695 $e 20160926 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...